Valuation: Milestone Pharmaceuticals Inc.

Market Cap 108M 95.59M 89.46M 81.08M 153M 10.38B 154M 1.07B 418M 5.3B 404M 396M 17.02B P/E 2026 *
-0.91x
P/E 2027 * -0.91x
Enterprise Value 108M 95.59M 89.46M 81.08M 153M 10.38B 154M 1.07B 418M 5.3B 404M 396M 17.02B EV / Sales 2026 *
28.1x
EV / Sales 2027 * 4.88x
Free-Float
99.3%
Yield 2026 *
-
Yield 2027 * -
1 day-1.95%
1 week-6.80%
Current month-11.72%
1 month-36.32%
3 months-42.11%
6 months-49.72%
Current year-62.17%
1 week 0.76
Extreme 0.7605
0.9
1 month 0.75
Extreme 0.7521
1.22
Current year 0.75
Extreme 0.7521
2.34
1 year 0.75
Extreme 0.7521
3.06
3 years 0.63
Extreme 0.6254
3.52
5 years 0.63
Extreme 0.6254
9.85
10 years 0
Extreme 0
27.95
Manager TitleAgeSince
Chief Executive Officer 59 2017-03-06
Director of Finance/CFO 53 2019-09-08
Compliance Officer 48 2026-02-09
Director TitleAgeSince
Director/Board Member 59 2017-06-30
Director/Board Member 60 2019-03-31
Director/Board Member 67 2020-09-30
Date Insider Type Main position Quantity % Market Cap. Importance
6/10/26 Free

Director

77,000 0.0618%
4/20/26 Buy

Chief Executive Officer

16,584 0.0141%
4/20/26 Buy

Chief Executive Officer

11,556 0.0098%
Change 5-day change 1-year change 3-year change Capi.($)
-1.95%-6.80%-63.95%-74.53% 108M
+4.16%+4.16%+49.37%+94.17% 74.69B
-1.65%-3.00%+20.97%+75.89% 58.81B
-0.09%+0.31%+6.81%+34.50% 48.45B
-3.76%-2.25%+329.09%+698.20% 42.84B
-2.30%-3.35%+26.81%+30.88% 42.79B
+0.31%-0.68%+5.30%+108.64% 41.25B
-0.11%+1.96%+9.19%+52.66% 31.13B
-2.07%+1.16%+35.00%+26.28% 30.28B
-1.96%-2.88%-8.97%-13.92% 24.05B
Average -0.94%-0.91%+40.96%+103.28% 39.44B
Weighted average by Cap. -0.38%-0.54%+55.37%+129.25%

Financials

2026 *2027 *
Net sales 3.83M 3.4M 3.18M 2.88M 5.44M 369M 5.48M 38.19M 14.86M 188M 14.37M 14.06M 605M 22.07M 19.59M 18.33M 16.62M 31.38M 2.13B 31.61M 220M 85.63M 1.09B 82.83M 81.05M 3.49B
Net income -117M -104M -96.98M -87.9M -166M -11.25B -167M -1.16B -453M -5.74B -438M -429M -18.46B -131M -116M -109M -98.53M -186M -12.61B -187M -1.31B -508M -6.44B -491M -481M -20.69B
Net Debt - -
Projected Income Statement - Annual - Milestone Pharmaceuticals Inc.
Logo Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc. is a Canada-based biopharmaceutical company. The Company is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The Company is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, and other cardiovascular indications.
Employees
38
Date Price Change Volume
26-10-06 US$0.7642 -1.95% 1,398,670
26-10-05 US$0.7794 -3.74% 1,084,583
26-10-02 US$0.8097 -0.74% 769,552
26-10-01 US$0.8157 -5.78% 725,593
26-09-30 US$0.8657 +5.57% 1,268,818
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Ratings Surperformance© - Milestone Pharmaceuticals Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
0.7642USD
Average target price
5.857USD
Spread / Average Target
+666.44%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Milestone Pharmaceuticals Inc.
  1. Stock Market
  2. Stocks
  3. MIST Stock